[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Universitas Indonesia\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":164},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,52,78,112,133],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100656875","hospital-based-prospective-cohort-of-malnutrition-under-6-month-study-hospic-6-study-100656875",false,"NCT07831343","Hospital-Based Prospective Cohort of Malnutrition Under 6-Month Study (HOSPIC-6-Study)","Acute Malnutrition in Infants Under 6 Months of Age Based on the 2023 WHO Criteria and Influencing Factors: A Multicenter Prospective Cohort in Hospital","HOSPIC-6","Inclusion criteria:\n\n* Infants under 6 months of age admitted to inpatient care who meet the WHO 2023 criteria for acute malnutrition.\n* For infants aged 0-1 month, criteria include a documented weekly weight gain of less than 200 grams, or failure to return to birth weight by 2 weeks of chronological age.\n* For infants aged 1 month to under 6 months, at least one of the following is required:\n\n  * Weight-for-age less than -2 SD\n  * Weight-for-length less than -2 SD, or\n  * Mid-upper arm circumference under 110 mm (for infants older than 6 weeks), with or without nutritional oedema, and currently receiving treatment for acute malnutrition.\n* Parents or legal guardians must provide written informed consent.\n\nExclusion criteria:\n\n* Infants with inborn error of metabolism\n* Infant with syndromic condition (e.g., Down syndrome, Silver-Russell syndrome, Turner syndrome, Klinefelter syndrome, or other diagnosed syndromic conditions),\n* Infant with anatomical abnormality affecting body weight, such as hydrocephalus.\n\nDrop Outs Criteria:\n\nParticipants will be considered \"drop-outs\" if they are discharged against medical advice or transferred to a non-participating hospital.","ALL","1 Day","6 Months",{"count":21,"type":22},1780,"ESTIMATED","OBSERVATIONAL","This study is a hospital-based, prospective, multicentre cohort study (the HOSPIC-6 Study) that will follow infants under 6 months of age who are admitted to pediatric or perinatology wards with acute malnutrition, diagnosed according to the 2023 WHO criteria. The study will take place at Cipto Mangunkusumo Hospital (RSCM) in Jakarta, Indonesia, together with other hospitals all over Indonesia joining the HOSPIC-6 network, over a period of about one year.\n\nThe purpose of this study is to:\n\n1. Describe how common acute malnutrition is among infants under 6 months admitted to these hospitals\n2. Observe what happens to these infants during nutrition treatment: whether they recover, whether their growth improves, or whether they experience complications or death.\n3. Look at the factors associated with succesful nutrition therapy outcomes.\n\nAfter enrolment, each infant's weight, length, head circumference, and mid-upper arm circumference will be measured using standardized techniques, along with information about their birth history, feeding history, and any other illnesses. These measurements, along with details of the nutrition therapy provided, will be repeated on day 3, day 7, and then weekly until the infant is discharged from the hospital. All data will be recorded in a secure, password-protected electronic database (REDCap). No experimental drug or intervention will be given as part of this study; infants will receive the nutrition care that their treating doctors already provide as standard practice, and the study will only observe and record what happens.\n\nThe information gathered from this study is expected to help doctors and health authorities better understand the scale of this problem in Indonesia and to support the development of clearer, evidence-based feeding and calorie guidelines for the treatment of acute malnutrition in infants under 6 months of age.",[26,27],"Malnutrition, Infant","Malnutrition",[27,29,30,31,32,33,34,35,36,37,38],"Infant","Acute Malnutrition","Wasting","Nutritional Oedema","Nutritional Therapy","Anthropometry","Mid-Upper Arm Circumference","Treatment Outcome","Prospective Cohort Studies","Infant Under 6 months","RECRUITING","2026-10-08",{"date":42,"type":43},"2026-10-09","ACTUAL",{"date":45,"type":43},"2026-08-28",{"date":47,"type":22},"2027-07-30",{"name":49,"class":50},"Universitas Indonesia","OTHER",6,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},"100657155","efficacy-of-thread-embedding-acupuncture-using-the-longitudinal-oblique-technique-from-bl40-toward-bl57-on-koos-scores-and-joint-range-of-motion-in-knee-osteoarthritis-100657155","NCT07833462","Efficacy of Thread-Embedding Acupuncture Using the Longitudinal Oblique Technique From BL40 Toward BL57 on KOOS Scores and Joint Range of Motion in Knee Osteoarthritis","Inclusion Criteria:\n\n* Male and female patients aged 51 to 70 years.\n* Clinically and radiologically diagnosed with bilateral knee osteoarthritis according to ACR (American College of Rheumatology) criteria.\n* Kellgren-Lawrence grade II or III knee osteoarthritis.\n* NRS (Numeric Rating Scale) score \\>3 during activity (activities of daily living or light exercise).\n* Body Mass Index (BMI) ≥18.5 kg\u002Fm².\n* Knee functional limitations assessable via the KOOS.\n* Ability to understand and complete the KOOS questionnaire. MMSE score \\>23 (normal or no significant cognitive impairment).\n* Willingness to complete the study and sign the informed consent form.\n\nExclusion Criteria:\n\n* History of knee surgery such as total knee replacement, arthroscopy, or ligament reconstruction.\n* Inflammatory joint disease or autoimmune conditions (e.g., rheumatoid arthritis, gouty arthritis, spondyloarthritis, or lupus arthritis) assessed via clinical symptoms and\u002For radiological findings.\n* Presence of a tumor, wound, or local infection at the injection site.\n* History of peripheral vascular disease, DVT\u002Fthromboembolism, aneurysm or pseudoaneurysm, or coagulation\u002Fbleeding disorders.\n* Presence of a blood disorder or use of blood thinners (combination antiplatelet or anticoagulant therapy) with an INR ≤ 2.0; history of spontaneous bleeding, thrombocytopenia, or coagulation disorders.\n* Uncontrolled diabetes mellitus or severe systemic disease with a random blood glucose (RBG) level ≥200 mg\u002FdL (measured via capillary blood using a glucometer).\n\nRandom blood glucose (RBG) level ≥200 mg\u002FdL in non-diabetic patients (measured via capillary blood using a glucometer for all study participants).\n\n* History of keloids.\n* Routine use of steroids or NSAIDs, or use of topical analgesics prior to therapy and during the study period.\n* Not currently receiving intra-articular knee injections (corticosteroids or hyaluronic acid) and has not received them in the last 3 months.\n* Presence of a Baker's cyst in the popliteal fossa, identified during physical examination.\n* Patients currently undergoing physiotherapy or who have undergone it within the last month.\n* Prior receipt of thread-embedding acupuncture therapy in the knee area or at acupuncture points BL40-BL57 within the last 6 months, or other forms of acupuncture within the last 2 weeks.\n* History of hypersensitivity or allergic reactions to polydioxanone (PDO) threads or procedure needle materials (e.g., stainless steel).","51 Years","70 Years",{"count":61,"type":22},44,"INTERVENTIONAL",[64],"NA","This study aims to evaluate the efficacy of thread embedding acupuncture using a longitudinal oblique technique from BL40 toward BL57 in patients with knee osteoarthritis. The effects of the intervention will be evaluated using the Knee Injury and Osteoarthritis Outcome Score (KOOS) and knee range of motion (ROM), compared with sham thread embedding acupuncture in a double-blind randomized controlled trial.",[67],"Knee Osteoarthritis","NOT_YET_RECRUITING","2026-10-04",{"date":71,"type":43},"2026-10-07",{"date":73,"type":22},"2026-09-23",{"date":75,"type":22},"2026-11-25",{"name":49,"class":50},1,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":17,"minAge":86,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":62,"phases":89,"briefSummary":90,"conditions":91,"keywords":94,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":77},"100659334","digital-cognitive-behavioral-therapy-for-gambling-disorder-a-pilot-randomized-controlled-trial-100659334","NCT07863440","Digital Cognitive Behavioral Therapy for Gambling Disorder: A Pilot Randomized Controlled Trial","Digital Cognitive Behavioral Therapy Versus Face-to-Face Cognitive Behavioral Therapy for Gambling Disorder: A Pilot Randomized Controlled Feasibility Trial","Indo CHIP","Inclusion Criteria for Patients With Gambling Disorder:\n\n* Aged 18 to 59 years.\n* Positive screening for gambling problems using the validated Indonesian version of the South Oaks Gambling Screen (SOGS), with a score of 5 or higher.\n* Diagnosis of gambling disorder according to ICD-11 criteria confirmed through a psychiatric interview conducted by an addiction psychiatrist.\n* Willing and able to provide written informed consent.\n* Has one eligible affected family member who is willing to participate and provide written informed consent.\n* Has access to the internet and a smartphone capable of accessing the digital intervention.\n\nExclusion Criteria for Patients With Gambling Disorder:\n\n* No history of gambling during the previous 6 months.\n* History of a neuropsychiatric disorder that would interfere with study participation.\n* Severe mental disorder or intellectual disability preventing adequate completion of study assessments or participation in CBT.\n* Severe agitation preventing adequate participation in CBT.\n* Previous pharmacological or non-pharmacological treatment specifically for gambling disorder (treatment-naive).\n\nInclusion Criteria for Participating Family Members:\n\n* 18 years or older.\n* Willing and able to provide written informed consent.\n* Is the parent, spouse, or sibling of the participating patient with gambling disorder.\n* Accompanies the patient during treatment and is affected by the patient's gambling behavior.\n* Has access to the internet and a smartphone capable of accessing the digital intervention.\n\nExclusion Criteria for Participating Family Members:\n\n• The associated patient withdraws from the study or otherwise becomes ineligible for continued study participation.","18 Years",{"count":88,"type":22},40,[64],"This pilot randomized controlled trial evaluates the feasibility, acceptability, and preliminary clinical effects of digital cognitive behavioral therapy (CBT) for adults with gambling disorder involving online gambling in Indonesia. Twenty patient-family dyads will be enrolled. Patients with gambling disorder will be randomized to receive either 12 sessions of digital CBT or 12 individualized face-to-face CBT sessions over approximately 6 weeks. Family members in the digital arm will receive six digital family-intervention sessions over 3 weeks, while family members in the comparator arm will receive the same six-session intervention in printed format. Gambling-related symptoms, urges, cognitions, psychological symptoms, depression, sleep quality, coping, readiness to change, and family-related outcomes will be assessed during treatment. Feasibility and acceptability of the digital interventions will also be evaluated.",[92,93],"Gambling Disorder","Gambling",[95,96,97,98,99,100,101,102,103,104],"Online gambling","Internet gambling","Gambling Addiction","Cognitive Behavioral Therapy","Digital CBT","Internet-Based CBT","Behavioral Addiction","Gambling Harms","Family","Affected Others","2026-10-02",{"date":71,"type":43},{"date":108,"type":22},"2026-11",{"date":110,"type":22},"2027-02",{"name":49,"class":50},{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":11,"sex":17,"minAge":86,"maxAge":118,"enrollmentInfo":119,"targetDuration":4,"studyType":62,"phases":121,"briefSummary":122,"conditions":123,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":77},"100657172","the-immediate-effects-of-dry-needling-acupuncture-on-pain-intensity-and-pressure-pain-threshold-in-patients-with-myofascial-pain-syndrome-of-the-upper-trapezius-100657172","NCT07833475","The Immediate Effects of Dry Needling Acupuncture on Pain Intensity and Pressure Pain Threshold in Patients With Myofascial Pain Syndrome of The Upper Trapezius","Inclusion Criteria:\n\n* Male or female participants aged 18-59 years with complaints of pain in the posterior neck and shoulder regions.\n* Myofascial trigger points (MTrPs) identified on palpation of the upper trapezius muscle.\n* Numeric Rating Scale (NRS) score of 4-6 and Pressure Pain Threshold (PPT) ≤ 3 kg\n* Willingness to participate in the study until completion and to sign the informed consent form.\n\nExclusion Criteria:\n\n* A previous diagnosis of cervical herniated nucleus pulposus (HNP).\n* History of thread-embedding acupuncture therapy in the upper trapezius muscle within the past 6 months.\n* History of dry needling (DN) and\u002For acupuncture therapy in the upper trapezius muscle within the past 1 week.\n* History of taking analgesic and anti-inflammatory medications within the past 24 hours.\n* Presence of a tumor, wound, or skin infection at the needling site.\n* History of hypersensitivity reactions to previous acupuncture therapy (metal allergy, severe atopy, keloids, or other skin hypersensitivity).\n* Presence of a blood disorder or use of anticoagulant medications (heparin and warfarin).\n* Pregnant women.","59 Years",{"count":120,"type":22},30,[64],"This study aims to evaluate the immediate effects of a single session of dry needling on pain intensity and pressure pain threshold in patients with myofascial pain syndrome of the upper trapezius muscle. Outcomes will be assessed using the Numeric Rating Scale (NRS) and Pressure Pain Threshold (PPT) before treatment and at 30 minutes, 24 hours, and 72 hours after treatment.",[124],"Myofascial Pain Syndrome","2026-09-16",{"date":127,"type":43},"2026-09-22",{"date":129,"type":22},"2026-09-30",{"date":131,"type":22},"2026-12-31",{"name":49,"class":50},{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":140,"minAge":86,"maxAge":4,"enrollmentInfo":141,"targetDuration":4,"studyType":62,"phases":143,"briefSummary":145,"conditions":146,"keywords":150,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":77},"100481546","phase-2-the-role-of-simvastatin-in-the-epithelial-mesenchymal-transition-process-of-breast-cancer-100481546","NCT05550415","The Role of Simvastatin in The Epithelial-Mesenchymal Transition Process of Breast Cancer","Vimentin Expression-based Therapeutic Response in Triple Negative Breast Cancer Receiving Combination of Simvastatin and NAC: A Randomized, Double-Blind, Placebo-Controlled Trial","Inclusion Criteria:\n\n1. Female patients with advanced breast cancer (locally advanced and distantly advanced) with triple-negative molecular type confirmed by biopsy and immunohistochemical examination.\n2. The patient planned to receive 8 cycles of AC-T chemotherapy.\n3. Patient age \\> 18 years.\n4. Willing to participate in research by signing informed consent.\n\nExclusion Criteria:\n\n1. The patient is pregnant or breastfeeding.\n2. Patients who have received chemotherapy or are on simvastatin therapy.\n3. Allergy to statins.","FEMALE",{"count":142,"type":22},26,[144],"PHASE2","Introduction: Most cases of Triple Negative Breast Cancer (TNBC) have a high proliferation rate. TNBC is associated with a poor prognosis, a high recurrence rate, and a high incidence of distant metastases. The Epithelial-Mesenchymal Transition process (EMT) plays an essential role in the metastatic process. EMT markers were also more abundant in TNBC and contributed to a poorer TNBC prognosis. As an important EMT marker, the increased expression of vimentin also contributed to the increase in TNBC aggressiveness and resistance to chemotherapeutic agents. Through the mechanism of action in inhibiting the mevalonate pathway, statins can help inhibit the EMT process in metastases. Notably, simvastatin promotes the down-regulation of vimentin in breast cancer cells. The combination of statins and neoadjuvant chemotherapy (NAC) improves the cancer patient's response. This study is expected to evaluate the role of a combination between NAC and simvastatin on therapeutic response in TNBC patients through vimentin expression.\n\nMethods: This study is a double-blind, randomized, placebo-controlled trial conducted in Dr. Cipto Mangunkusumo National Central General Hospital. An expected total of 26 TNBC patients will be assessed for eligibility and asked for informed consent. Patients with the plan to have ACT (Doxorubicin hydrochloride, Cyclophosphamide, Paclitaxel) chemotherapy regimen will receive either a combination of ACT-Simvastatin (40 mg\u002Fday) or ACT-Placebo. The biopsy will be taken pre-NAC to make the histopathological diagnosis and examine the expression of vimentin. Patients will be evaluated for adverse effects reaction every cycle and the clinical response after 8 cycles. The post-intervention biopsy will be conducted after the cycle finish. The pathological response and vimentin expression will be reviewed from the obtained samples.",[147,148,149],"Triple Negative Breast Cancer","Chemotherapy Effect","Simvastatin Adverse Reaction",[151,152,153,154,155,156],"Vimentin","Simvastatin","Epithelial-Mesenchymal Transition","Neoadjuvant Chemotherapy","Clinical Response","Pathological Response",{"date":158,"type":43},"2026-09-21",{"date":160,"type":43},"2022-08-19",{"date":162,"type":22},"2026-12",{"name":49,"class":50},""]